Christopher R Kinsinger
Christopher R Kinsinger
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,‡,
James Apffel
James Apffel
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Mark Baker
Mark Baker
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Xiaopeng Bian
Xiaopeng Bian
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Christoph H Borchers
Christoph H Borchers
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Ralph Bradshaw
Ralph Bradshaw
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Mi-Youn Brusniak
Mi-Youn Brusniak
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Daniel W Chan
Daniel W Chan
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Eric W Deutsch
Eric W Deutsch
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Bruno Domon
Bruno Domon
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Jeff Gorman
Jeff Gorman
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Rudolf Grimm
Rudolf Grimm
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
William Hancock
William Hancock
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Henning Hermjakob
Henning Hermjakob
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
David Horn
David Horn
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Christie Hunter
Christie Hunter
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Patrik Kolar
Patrik Kolar
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Hans-Joachim Kraus
Hans-Joachim Kraus
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Hanno Langen
Hanno Langen
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Rune Linding
Rune Linding
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Robert L Moritz
Robert L Moritz
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Gilbert S Omenn
Gilbert S Omenn
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Ron Orlando
Ron Orlando
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Akhilesh Pandey
Akhilesh Pandey
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Peipei Ping
Peipei Ping
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Amir Rahbar
Amir Rahbar
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Robert Rivers
Robert Rivers
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Sean L Seymour
Sean L Seymour
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Richard J Simpson
Richard J Simpson
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Douglas Slotta
Douglas Slotta
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Richard D Smith
Richard D Smith
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Stephen E Stein
Stephen E Stein
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
David L Tabb
David L Tabb
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Danilo Tagle
Danilo Tagle
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
John R Yates III
John R Yates III
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1,
Henry Rodriguez
Henry Rodriguez
1From the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Agilent Research Laboratories, Santa Clara, California 95051, the Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia, the Center for Bioinformatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia V8Z 7X8, Canada, the Mass Spectrometry Facility, University of California, San Francisco, California 94143, the Institute of Systems Biology, Seattle, Washington 98103, the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, the Institute for Systems Biology, Seattle, Washington 98109, the Luxembourg Clinical Proteomics Center, CRP-Sante, Strassen L-1445, Luxembourg, the Protein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia, Agilent Technologies, Santa Clara, California 95051, the Department of Chemistry & Chemical Biology, Northeastern University, Boston, Massachusetts 02115, Proteomics Services, European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom, Proteomics Software Strategic Marketing, Thermo Fisher Scientific, San Jose, California 95134, AB SCIEX, Foster City, California 94404, the Directorate-General for Research, European Commission, Brussels B-1049, Belgium, Wiley-VCH, Weinheim D-69469, Germany, Exploratory Biomarkers, Hoffmann-La Roche, Basel 4070, Switzerland, the Technical University of Denmark, Cellular Signal Integration Group, Center for Biological Sequence Analysis, Department of Systems Biology DK-2800 Lyngby, Denmark, the Cellular & Molecular Logic Unit, Institute of Systems Biology, Seattle, Washington 98103, the Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland 21231, the David Geffen School of Medicine, University of California, Los Angeles, California 90095, the Small Business Development Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, AB Sciex, Foster City, California 94404, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia, the National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland 20892, the Pacific Northwest National Laboratory, Richland, Washington 99352, the Chemical Reference Data Group, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, the Scripps Research Institute, La Jolla, California 92037, and the Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
1